Kathmandu: Research carried out in the UK has found that a new daily pill may shrink tumours in people with pancreatic cancer, one of the deadliest and hardest to treat cancers. Experts are calling daraxonrasib the biggest advance in pancreatic cancer treatment in decades, according to BBC News.

In early trials, cancer could no longer be seen on scans in one in 12 patients who took the drug with chemotherapy. Tumours stopped growing in almost all of the 61 patients, who had recently been diagnosed with advanced pancreatic cancer that had spread to other parts of the body.

Doctors say it is too early to know how long the drug can keep the disease away. They say it should not be seen as a cure.

Pancreatic cancer has the lowest survival rate of all common cancers. Chemotherapy can shrink tumours a little but the cancer often grows back and most people with advanced disease live for months, not years. Doctors hope the new drug can give patients more time, even if it cannot stop the cancer for good.

What the trial found

In the phase I/II trial, patients were followed for about a year and a half on average. Some did not see their cancer return in that time.

  • Tumours stopped growing in 90% of patients.
  • Just over 60% of patients saw their tumours shrink or disappear.
  • About 8% of patients or one in 12 had tumours that could not be seen on CT scans.

Dr Wungki Park of Memorial Sloan Kettering Cancer Center in the US, who is involved in the trial, called the results extremely encouraging so far. He said more patients are responding, the responses are deeper and disease control lasts almost twice as long. This may eventually mean longer survival.

How the drug works

Daraxonrasib is a KRAS inhibitor that has already been approved in the US. It locks on to a group of mutations called RAS and switches them off.

These mutations drive tumour growth in most pancreatic cancers. Dozens of other cancers, including lung and ovarian cancer, can have similar mutations, so the drug might help many other patients.

What experts say

Cancer Research UK called the results the biggest leap forward in decades for pancreatic cancer patients. Dr Sam Godfrey from the charity told BBC News the results were incredibly exciting.

He said the drug has found a way to target a cancer driver that was once thought untargetable and that progress in pancreatic cancer was long overdue. He hopes the early success can be repeated in other cancers.

Prof Elena Garralda chairs the European cancer conference EORTC, where the work is being shared with other doctors. She said the combined treatment could greatly improve overall survival and lengthen the time before tumours start growing again.

Dr Godfrey said cancer can come back and that patients cannot be sure they are cancer free until more time has passed, even if scans show no sign of it. Longer studies are needed to find out whether any of these cancers can go into remission and for how long.

With inputs from agencies.